Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT02036489Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jan 2008
- Primary completion
- Dec 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of vincristine, daunorubicin, prednisone, asparaginase escherichia coli, cyclophosphamide in acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Started Jan 2008; status: completed.
02
Drugs
vincristinedaunorubicinprednisoneasparaginase escherichia colicyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02036489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036489.